Meeting
2019 ASCO Annual Meeting
Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring program.
Authors
Stefanie L. Groenland
The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
Stefanie L. Groenland , Andre M. Bergman , Alwin Huitema , Neeltje Steeghs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Pharmacology/Pharmacodynamics/Pharmacogenetics
Clinical Trial Registration Number
NL6695
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3117)
DOI
10.1200/JCO.2019.37.15_suppl.3117
Abstract #
3117
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa
Poster
2024 ASCO Annual Meeting
Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy.
First Author: Ning Lee
Poster
2023 ASCO Annual Meeting
Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.
First Author: Gregory Feng
Poster
2023 ASCO Genitourinary Cancers Symposium
Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Alexandre Xu-Vuillard